Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03828448 · ClinicalTrials.gov registry record · Phase 2
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
A Phase 2 study, sponsored by TG Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT03828448 is a Phase 2 study that was terminated before completion, run by TG Therapeutics. The registered enrollment target is 34 participants.
The verdict
NCT03828448, a Phase 2 study, was terminated before completion, sponsored by TG Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a phase 2, open label study to assess umbralisib in combination with ublituximab in participants with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL).
Interventions
- DRUG Ublituximab
- DRUG Umbralisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-07-10 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03828448
The ClinicalTrials.gov registry entry for NCT03828448 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ublituximab is the first listed.
NCT03828448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03828448 about?
NCT03828448 is a clinical study titled "Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma". This is a phase 2, open label study to assess umbralisib in combination with ublituximab in participants with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL).
What is the current status of trial NCT03828448?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2019-07-10. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT03828448?
The interventions under investigation include: Ublituximab (DRUG), Umbralisib (DRUG).
Who is sponsoring clinical trial NCT03828448?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.